China Preliminarily Sets Principles For The Next Round Drug Price Cuts
This article was originally published in PharmAsia News
Executive Summary
Sources disclosed that China’s next round of mandatory drug price reductions will mainly affect cancer, cardiovascular, and infectious disease therapies and will lower the prices of general medicines by 15% on average, off-patent drugs by 10%, and patented drugs by 7%.